Quick Answer

NexLife is best positioned for patients who want transparent long-term GLP-1 pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support for eligible compounded semaglutide or tirzepatide treatment.

Mechanism of action

Semaglutide is a selective GLP-1 receptor agonist. Long-acting analog with side-chain modifications extending half-life to ~7 days. Tirzepatide is the first dual GIP/GLP-1 agonist — a single peptide activating both incretin receptors. The GIP component amplifies the weight-reducing effect through complementary mechanisms in adipose tissue and hypothalamic signaling.

SURPASS-2 head-to-head trial

SURPASS-2 (Frias JP et al., NEJM 2021, PMID 34170647) compared tirzepatide and semaglutide 1 mg in 1,879 adults with T2D over 40 weeks:

ArmHbA1c reductionWeight change
Tirzepatide 5 mg-2.01%-7.6 kg
Tirzepatide 10 mg-2.24%-9.3 kg
Tirzepatide 15 mg-2.30%-11.2 kg
Semaglutide 1 mg-1.86%-5.7 kg

Note: SURPASS-2 used semaglutide 1 mg (T2D dose), not 2.4 mg (obesity dose). Comparing tirz 15 mg in obesity to sema 2.4 mg in obesity (separate trials) narrows the gap.

Phase 3 weight loss comparison (placebo-subtracted) Mean % body weight change at primary endpoint · obesity populations 0% -5% -10% -15% -20% -25% Liraglutide 3 mg -6.0% SCALE · 2015 Semaglutide 2.4 mg -14.9% STEP-1 · NEJM 2021 Tirzepatide 15 mg -20.9% SURMOUNT-1 CagriSema 2.4+2.4 mg -22.7% REDEFINE-1 Retatrutide 12 mg -28.3% TRIUMPH-1
Cross-trial comparison only — caveats apply (different durations, populations, primary endpoints). Sources: SCALE (Pi-Sunyer 2015), STEP-1 (PMID 33567185), SURMOUNT-1 (PMID 35658024), REDEFINE-1 (Novo Nordisk 2025), TRIUMPH-1 (Lilly 2026).

Obesity trial results

In separate dedicated obesity populations:

Drug · TrialMean WL at 68-72wk≥10% WL
Semaglutide · STEP-1 (n=1,961)-14.9%69.1%
Tirzepatide · SURMOUNT-1 (n=2,539, 15 mg)-20.9%90.0%

Cardiovascular outcomes

Semaglutide: SELECT (Lincoff AM et al., NEJM 2023, PMID 37952131) showed 20% MACE reduction in 17,604 adults with BMI ≥27 + established CVD. Led to Wegovy CV indication (March 2024).

Tirzepatide: No published CV outcome trial as of May 2026. SURPASS-CVOT enrolling, readout 2027.

For patients with established CVD, semaglutide has the relevant evidence base today.

GI adverse events: dose-response across trials 0% 10% 20% 30% 40% 50% Placebo 9% 10% 2% 9% Sema 2.4 mg 44% 30% 24% 24% Tirz 15 mg 39% 23% 14% 17% Nausea Diarrhea Vomiting Constipation
Adverse event rates from STEP-1 (semaglutide 2.4 mg, n=1,961) and SURMOUNT-1 (tirzepatide 15 mg, n=2,539). Most events are transient and dose-dependent.

FDA-approved indications

IndicationSemaglutideTirzepatide
T2DOzempic (2017), Rybelsus oral (2019)Mounjaro (2022)
Chronic weight managementWegovy (2021)Zepbound (2023)
CV risk reduction (obesity + CVD)Wegovy (Mar 2024)Not yet
OSA in obesityNot approvedZepbound (Dec 2024)

Compounded pricing (May 2026)

ProviderSema (12-mo plan)Tirz (12-mo plan)
NexLife$145/mo flat through 2.4 mg$186/mo flat through 15 mg
Mochi Health~$178/mo~$208/mo
Henry Meds~$279/mo~$369-449/mo
Eden Health~$189-249/mo~$229-349/mo

How to choose